Research programme: anticancer therapeutics - MNLpharma/Zetiq
Alternative Names: Anticancer therapeutics research programme - MNLpharma/ZetiqLatest Information Update: 25 May 2007
At a glance
- Originator MNLpharma; Zetiq Technologies
- Class
- Mechanism of Action Undefined mechanism
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Jul 2003 Preclinical trials in Cancer in United Kingdom (unspecified route)
